Purchase this article with an account.
Baljean Dhillon, Alan F. Wright, Adnan Tufail, Isabel Pappworth, Caroline Hayward, Iain Moore, Lisa Strain, David Kavanagh, Paul N. Barlow, Andrew P. Herbert, Christoph Q. Schmidt, Ana-Maria Armbrecht, Augustinus Laude, Ian J. Deary, Scott J. Staniforth, Lucy V. Holmes, Timothy H. J. Goodship, Kevin J. Marchbank; Complement Factor H Autoantibodies and Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(11):5858-5863. doi: 10.1167/iovs.09-5124.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In this case-control study, the hypothesis that factor H autoantibodies are associated with age-related macular degeneration (AMD) was examined.
One hundred AMD patients (median age, 78 years), 98 age-matched control subjects (median age, 78 years) known not to have AMD, and 100 healthy blood donors (median age, 43 years) were enrolled. An enzyme-linked immunosorbent assay (ELISA) was used to screen for complement factor H autoantibodies and either quantitative polymerase chain reaction (qPCR) or multiplex ligation–dependent probe amplification (MLPA) were performed to measure the copy number of the gene encoding complement factor H–related protein 3 (CFHR3).
There was a significant difference in the median complement factor H autoantibody titer between the three groups (AMD patients, 196 reference units [RU]]; age-match control subjects, 316 RU; and blood donor control subjects, 121 RU; Kruskal-Wallis test, P < 0.001). Pair-wise comparison (Mann-Whitney test) showed that all three groups were significantly different from each other. Two different thresholds were used in the healthy blood donors to identify individuals with complement factor H autoantibodies. Both suggested that the prevalence of factor H autoantibodies was decreased in AMD patients. The CFHR3 copy number was measured as a surrogate for the deletion of the genes encoding complement factor H–related proteins 3 and 1 (CFHR3/1). The allele frequency of the deletion was significantly higher in the age-matched control subjects than in the AMD patients (22.2% vs. 8.2%).
The level of factor H autoantibodies is lower in AMD patients than in age-matched control subjects.
This PDF is available to Subscribers Only